The primary benefits of liraglutide include: Clinically meaningful weight loss (6 to 8% average, up to 10%+ in early responders) Improved glycemic control and HbA1c reduction in type 2 diabetes Demonstrated cardiovascular risk reduction (13% reduction in MACE in the LEADER trial) Reduced progression from prediabetes to type 2 diabetes Approved for adolescents aged 12+ (obesity) and children aged 10+ (diabetes) The longest safety track record of any GLP-1 receptor agonist How It Works GLP-1 Receptor Activation Liraglutide functions as a potent agonist at GLP-1 receptors distributed throughout the pancreas, brain, heart, and gastrointestinal tract
J Neurosci 29(35):1102911037
Only trained personnel should work with retatrutide in controlled facilities
This dual agonist action appears to have additive effects, leading to enhanced insulin release, greater appetite suppression, and potentially more substantial weight loss
do not use it if you or a family member has had medullary thyroid carcinoma or MEN 2
Omdat veel patinten na verloop van tijd stoppen met het medicijn en dan weer aankomen, bestaat het risico dat zij vooral vetmassa terugwinnen terwijl de verloren spiermassa niet volledig herstelt